Perfecting Breast-Cancer Treatment — Incremental Gains and Musculoskeletal Pains
Mené sur 3 066 patientes atteintes d'un cancer du sein HR+ de stade précoce avant la ménopause, cet essai évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'ajout de la suppression de la fonction ovarienne au tamoxifène en traitement adjuvant (durée médiane de suivi : 67 mois)
A fundamental feature of adjuvant therapy (treatment of apparently disease-free people to reduce the risk of recurrence) is that many are treated to benefit a few. The options for the adjuvant treatment of hormone-sensitive breast cancer have expanded in recent years. On the basis of meta-analyses of individual-patient data in studies dating back to 1985, tamoxifen has remained the standard of care in breast cancer. Tamoxifen reduces the annual rates of breast-cancer recurrence by almost half and mortality by one third. In absolute terms, this translates to 11.8 fewer recurrences and 9.2 fewer deaths per 100 women at 15 years. The benefits are similar for both younger women and older women...
New England Journal of Medicine , éditorial en libre accès, 2013